Enrolling by invitation NCT03296605
Development of Obesity and Bariatric Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Obesity. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Impacts of Bariatric Surgery on Obesity in China
Overview
This study focus on the cause of obesity and impacts of bariatric surgery on it.
Primary outcome measures
- Immunity cells [Time frame: up to 5 years]
Secondary outcome measures (9)
- Body weight and height [Time frame: up to 5 years]
- Insulin [Time frame: up to 5 years]
- Cytokine [Time frame: up to 5 years]
- Cognitive Assessment (MMSE) [Time frame: up to five years]
- Cognitive Assessment (MoCA) [Time frame: up to 5 years]
- Cognitive Assessment (RBANS) [Time frame: up to 5 years]
- Cognitive Assessment (processing speed) [Time frame: up to 5 years]
- Cognitive Assessment (executive function) [Time frame: up to 5 years]
- brain structure and activation in fMRI [Time frame: up to 5 years]
Eligibility criteria
Inclusion criteria
- Body mass index ≥18 kg/m2
- already received bariatric surgery or abdonimal surgery
Exclusion criteria
- acute stroke or acute myocardial infarction in 6 months
- autoimmune disease
- long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs
- pregnancy
- consists with other endocrine diseases
- acute infection in2 weeks
- cancer
- use of antibiotics in 3 months
- chronic digestive inflammations 9
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
China · 1 center
- at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University — Nanjing
Publications
- Fang D, Yu X, Zhang P, Feng W, Hong T, Gu T. The beneficial effect of hepatic ER stress-associated protein PDI on obesity-associated glucose dysregulation. Nutr Metab (Lond). 2025 Nov 28;22(1):145. doi: 10.1186/s12986-025-01041-9. PMID 41316343
- Tang W, Ge K, Shen L, Wang H, Feng W, Sun X, Chu X, Zhu D, Yin H, Bi Y. Th1 bias of liver mucosal-associated invariant T cells promotes hepatic gluconeogenesis in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2023 May;39(4):e3620. doi: 10.1002/dmrr.3620. Epub 2023 Feb 17. PMID 36738300
- Liu F, He J, Liu B, Zhang P, Wang H, Sun X, Chu X, Guan W, Feng W, Bi Y, Zhu D. Association of Omental Adipocyte Hypertrophy and Fibrosis with Human Obesity and Type 2 Diabetes. Obesity (Silver Spring). 2021 Jun;29(6):976-984. doi: 10.1002/oby.23155. Epub 2021 May 4. PMID 33943025
- Yuan X, Chen J, Cheng Q, Zhao Y, Zhang P, Shao X, Bi Y, Shi X, Ding Y, Sun X, Xue B. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery. BMC Gastroenterol. 2018 Oct 3;18(1):147. doi: 10.1186/s12876-018-0871-2. PMID 30285651
- Zhang P, Ge Z, Wang H, Feng W, Sun X, Chu X, Jiang C, Wang Y, Zhu D, Bi Y. Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol. 2018 Jun;68(6):1247-1255. doi: 10.1016/j.jhep.2018.01.035. Epub 2018 Feb 13. PMID 29452209
Identifiers
NCT: NCT03296605 · AF/SC-08/02.0